Abstract 19087: Handgrip Strength Relates to Peak Oxygen Consumption in Heart Failure and Non-Heart Failure Patients
Background: The cardinal feature of heart failure (HF) is exercise intolerance. Skeletal muscle dysfunction is thought to be a major contributor to exercise intolerance. Cardiopulmonary exercise capacity described by peak oxygen consumption (pVO2) is a commonly used test of functional capacity and is a powerful prognostic indicator. Maximal testing is often restricted by patient mobility and co-morbidities. Handgrip strength (HGS) is related to pVO2 in other disease states but whether this is the case in HF remains unknown. We aimed to determine the relationship between HGS and pVO2 in HF and non-HF patients.
Methods: A cross-sectional study of 41 HF and 15 non-HF patients referred for cardiopulmonary testing. Clinical characteristics, cardiopulmonary testing derived measures, maximum HGS and endurance HGS (using a Lafeyette hydraulic handynamometer) were evaluated. Differences between groups and relationships between variables were assessed using Students t-test and Pearson’s correlation coefficient test respectively. Continuous variables are described as means (standard error). A p-value of <0.05 was taken to infer significance.
Results: HF and non-HF patients had similar ages (66.2 (2.0) v 67.8 (2.3), p=0.61). HF patients had significantly lower left ventricular ejection fraction (35.2 (2.3) v 55.6 (82.1), p<0.001). Neither measure of Handgrip strength differed between the two patient cohorts (Max HGS: 26.2 (1.7) v 26.1 (2.4), p=0.96, Endurance HGS: 19.4 (1.3) v 18.3 (1.2), p=0.53). In the complete cohort average maximum HGS significantly correlated with pVO2 in both HF and non-HF patients (r=0.34, p=0.029 and r=0.782, p<0.001 respectively). HGS was not associated with left ventricular ejection fraction in either HF or non-HF patients (r=0.124, p=0.454 and r=0.021, p=0.943).
Conclusion: Handgrip strength is closely related to pVO2 but not left ventricular ejection fraction in both HF and non-HF patients, suggestive of widespread skeletal muscle dysfunction in HF.
Author Disclosures: J. Woodcock-Shaw: None. M.F. Paton: None. J. Gierula: None. J. Lowry: None. M.T. Kearney: None. K.K. Witte: Other Research Support; Modest; NIHR Clinician Scientist Award.
- © 2016 by American Heart Association, Inc.